An evaluation of serum osteocalcin in pacet's disease of bone and its response to diphosphonate treatment
- 1 September 1988
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 31 (9) , 1142-1147
- https://doi.org/10.1002/art.1780310909
Abstract
We found that serum bone γ‐carboxyglutamic acid–containing protein (BGP) (osteocalcin) had lower sensitivity and specificity for measurement of disease activity in Paget's disease of bone than other biochemical measures of disease activity. The administration of diphosphonates induced suppression of urinary hydroxyproline excretion and a subsequent decrease in alkaline phosphatase values, but no consistent change in BGP values. Serum BGP measurements have limited value as a screening test for Paget's disease or for monitoring treatment of the disorder.This publication has 16 references indexed in Scilit:
- Serum Osteocalcin Concentrations in Paget's Disease of BoneArchives of internal medicine (1960), 1986
- Serum osteocalcin concentrations in Paget's disease of boneArchives of internal medicine (1960), 1986
- SERUM BONE GLA-PROTEIN: A SPECIFIC MARKER FOR BONE FORMATION IN POSTMENOPAUSAL OSTEOPOROSISThe Lancet, 1984
- Biochemical markers of bone turnover in paget's diseaseMetabolic Bone Disease and Related Research, 1981
- Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma.Proceedings of the National Academy of Sciences, 1980
- Primary structure of the gamma-carboxyglutamic acid-containing protein from bovine bone.Proceedings of the National Academy of Sciences, 1976
- Direct identification of the calcium-binding amino acid, gamma-carboxyglutamate, in mineralized tissue.Proceedings of the National Academy of Sciences, 1975
- Primer on Certain Elements of Medical Decision MakingNew England Journal of Medicine, 1975
- DIPHOSPHONATES IN PAGET'S DISEASEThe Lancet, 1974